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Objectives: The aim of this study was to determine the antimicrobial resistance patterns of 125
Campylobacter jejuni and 27 Campylobacter coli isolates from 39 Queensland broiler farms.
Methods: Two methods, a disc diffusion assay and an agar-based MIC assay, were used. The disc
diffusion was performed and interpreted as previously described (Huysmans MB, Turnidge JD. Disc sus-
ceptibility testing for thermophilic campylobacters. Pathology 1997; 29: 209–16), whereas the MIC assay
was performed according to CLSI (formerly NCCLS) methods and interpreted using DANMAP criteria.
Results: In both assays, no C. jejuni or C. coli isolates were resistant to ciprofloxacin or chloramphenicol,
no C. coli were resistant to nalidixic acid, and no C. jejuni were resistant to erythromycin. In the MIC
assay, no C. jejuni isolate was resistant to nalidixic acid, whereas three isolates (2.4%) were resistant in
the disc assay. The highest levels of resistance of the C. jejuni isolates were recorded for tetracycline
(19.2% by MIC and 18.4% by disc) and ampicillin (19.2% by MIC and 17.6% by disc). The C. coli isolates
gave very similar results (tetracycline resistance 14.8% by both MIC and disc; ampicillin resistance 7.4%
by MIC and 14.8% by disc).
Conclusions: This work has shown that the majority of C. jejuni and C. coli isolates were susceptible to
the six antibiotics tested by both disc diffusion and MIC methods. Disc diffusion represents a suitable
alternative methodology to agar-based MIC methods for poultry Campylobacter isolates.
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Introduction
Campylobacter is the most common bacterial cause of food-
borne disease in Australia.1 Contaminated animal products, par-
ticularly undercooked or raw poultry meat and raw milk, are
recognized as being the primary vehicles of human infections.2
Although most cases of Campylobacter infection are acute and
self-limited in nature and do not require antibiotic treatment,3
antibiotic treatment may be necessary in severe cases or immu-
nocompromised patients.4
There is little Australian data on the levels of antibiotic
resistance in animal isolates of Campylobacter. The only exten-
sive prior Australian study5 used a disc diffusion method to
examine 213 poultry isolates.
We report on the antimicrobial susceptibility patterns
present in 125 Campylobacter jejuni and 27 Campylobacter coli
isolates collected from 39 broiler farms in South-East
Queensland.
Materials and methods
Bacteria and growth conditions
The 125 C. jejuni and 27 C. coli isolates used in this study were
all confirmed by PCR6 and were obtained during a large epide-
miological study. The C. jejuni isolates came from 39 broiler
farms, and the C. coli isolates came from 14 farms (all farms
being a subset of the 39 farms yielding the C. jejuni isolates).
All the isolates had been genotyped by the flaA restriction frag-
ment length polymorphism method.7 Multiple isolates from a
farm were included, provided that the isolates showed different
genotypes.
Escherichia coli ATCC 25922, Pseudomonas aeruginosa
ATCC 27853 and Staphylococcus aureus ATCC 25923 were
used as control strains.
Incubation of Campylobacter species was performed at 37ºC
in a modified atmosphere incubator with a microaerobic
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
*Corresponding author. Tel: þ61-7-33629520; Fax: þ61-7-33629429; E-mail: jillian.templeton@dpi.qld.gov.au
Journal of Antimicrobial Chemotherapy (2007) 59, 775–778
doi:10.1093/jac/dkm024
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
775






/jac/article/59/4/775/679391 by guest on 29 Septem
ber 2020
atmosphere of 5% O2, 10% CO2 and 85% N2. The other bacteria
were incubated at 378C in air.
Antimicrobial susceptibility testing—disc diffusion
The disc diffusion methodology was based on the National
Committee for Clinical Laboratory Standards.8 The disc content
was as follows: ampicillin, 10 mg; chloramphenicol, 30 mg;
ciprofloxacin, 5 mg; erythromycin, 15 mg; nalidixic acid, 30 mg
and tetracycline, 30 mg. All discs were sourced from Oxoid. The
isolates were grown on brain heart infusion agar (Becton
Dickinson no. 4311037) containing 5% sheep blood cells
(BioMerieux no. 04378) at 378C for 48 h in the modified atmos-
phere incubator described earlier. The CLSI (formerly NCCLS)
method8 was followed using a growth method inoculum, with
the exception that the turbidity of the inoculum was adjusted to
the equivalent of a 1.0 McFarland turbidity standard. A purity
check, performed by inoculation onto sheep blood agar, was per-
formed for all suspensions. The inoculated Mueller–Hinton agar
(MHA) with lysed horse blood (Oxoid no. PP2097) and purity
check plates were incubated for 44–48 h at 378C in the modified
atmosphere incubator. For each test run, E. coli ATCC 25922,
P. aeruginosa ATCC 27853 and S. aureus ATCC 25923 were
used as control strains. The control strains were tested using
MHA (Oxoid no. PP2096) plates incubated aerobically at 378C.
The results for the control strains were read after 18–24 h of
incubation. The interpretation of susceptible, intermediate and
resistant was based on the criteria of Huysmans and Turnidge9
(Table 1).
Antimicrobial susceptibility testing—MIC testing
The MIC testing was done by a standardized agar dilution
method,8 with the exception that the turbidity of the inoculum
was adjusted to the equivalent of a 1.0 McFarland turbidity
standard. The inoculated MHA and purity check plates were incu-
bated for 44–48 h at 378C in the modified atmosphere incubator.
For each test run, control strains (all three listed above) were used
(as described above). The results for the control strains were read
after 18–24 h of incubation, whereas the Campylobacter results
were read after incubation for 44–48 h.
Antibiotics were tested in a 2-fold concentration series: ampi-
cillin, 0.25–64 mg/L; chloramphenicol, ciprofloxacin and ery-
thromycin, 0.25–32 mg/L; nalidixic acid, 1–128 mg/L and
tetracycline, 0.25–128 mg/L. The presence of growth was deter-
mined by visual examination and the MIC defined as the lowest
concentration of the antibiotic to prevent growth. Interpretation
of the results of the Campylobacter isolates was performed
using the resistance breakpoints published by DANMAP2004.10
As DANMAP200410 does not contain a breakpoint for ampicil-
lin, we used the resistance breakpoint used by the CLSI for
ampicillin resistance in Enterobacteriaceae (32 mg/L). The
breakpoints are shown in Table 1.
Statistical analysis
The overall level of resistance to at least one antibiotic in the C.
jejuni and C. coli isolates was compared by x2 analysis
(Statistix Software).
Results
The results of the disc diffusion and MIC testing are shown in
Table 2. At all times, the results from the control strains were
within the range indicated as acceptable by the relevant CLSI
guidelines.8
There was a strong agreement in the MIC and disc diffusion
methods for all six antibiotics tested for both Campylobacter
species (Table 2).
The level of resistance to any antibiotic examined in this
study never exceeded 20% for either C. jejuni or C. coli. Among
the 125 C. jejuni isolates, the highest level of resistance was to
tetracycline (19.2% by MIC and 18.4% by disc) and ampicillin
(19.2% by MIC and 17.6% by disc). A similar level of resist-
ance to these same two antibiotics was found in the 27 C. coli
isolates tested (Table 2). A low level of resistance to nalidixic
acid (2.4%) was found in the C. jejuni isolates by disc, whereas
all the C. jejuni isolates were susceptible by MIC. All C. coli
isolates were susceptible to this antibiotic by MIC and disc
methods. A low level of resistance (11.1% by MIC and disc)
was found to erythromycin among the C. coli isolates, whereas
Table 1. Interpretation criteria used in this study
Antibiotica
Zone diameter (mm) indicatingb
Resistant breakpoint (mg/L)S I R
Ampicillin (10 mg) 10 n/a 9 32c
Chloramphenicol (30 mg) 23 12–22 11 32
Ciprofloxacin (5 mg) 24 19–23 18 4
Erythromycin (15 mg) 19 16–18  15 32
Nalidixic acid (30 mg) 15 n/a 14 32
Tetracycline (30 mg) 33 16–32 15 16
The disc diffusion criteria were suggested by Huysmans and Turnidge,9 whereas the MIC breakpoints, except where indicated, are from DANMAP 2004.10
aThe figure in brackets is the amount of antibiotic in the disc.
bS, susceptible; I, intermediate; R, resistant.
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all C. jejuni isolates were susceptible to this agent by both MIC
and disc methods.
Resistance to more than one antibiotic was detected by disc
diffusion in 9 C. jejuni isolates (7.2%) and by MIC in 11 C.
jejuni isolates (8.8%). All of these isolates were resistant to both
tetracycline and ampicillin. By disc diffusion and MIC methods,
none of the 27 C. coli isolates showed resistance to more than
one antibiotic.
The overall level of resistance (by both disc diffusion and
MIC methods) was not significantly different in C. jejuni and C.
coli.
There were four broiler farms that contributed nine or more
isolates of C. jejuni to this study. In all of these cases, the geno-
typing indicated that—within the farm—all the isolates tested
were distinct and different genotypes. The occurrence of resist-
ance to ampicillin and tetracycline was not uniform within a
farm—isolates ranging from 11.1% to 30% for ampicillin and
from 18.2% to 30% for tetracycline.
Discussion
The on-going studies on the epidemiology of Campylobacter in
broilers in our laboratory allowed the selection of isolates across
a large number of broiler farms (39 in total). At the time these
studies were performed, the number of broiler farms in the
South-East Queensland region was estimated to be 120. Hence,
our study—based on 33% of the existing farms—provides a
sound insight into the prevalence of antimicrobial resistance in
Campylobacter associated with Queensland poultry. Our selec-
tion of isolates was further guided by our knowledge, arising
from the epidemiological studies, of the different genotypes of
C. jejuni/coli present within a flock. This knowledge of geno-
type allowed us to include multiple isolates from within a
flock—with the knowledge that each isolate represented a differ-
ent genotype. In contrast, the prior Australian study5 was based
on isolates obtained from either carcass rinses or intestinal
samples—with no information on the genetic diversity or farm
of origin available.
The level of resistance we found to tetracycline for C. jejuni
and C. coli was at the lower range of that reported in the prior
Australian study (15–36%).5 Higher levels of tetracycline resist-
ance have been reported from four European Union countries
(35.4%)11 and the USA (43%).12 In Sweden, where tetracycline
has not been added to chicken feed since 1986,13 the level of
tetracycline-resistant Campylobacter has been reported to be
1%.13
The level of resistance to ampicillin among both our
C. jejuni and C. coli isolates was similar to that reported in
other countries such as Germany (20% for C. jejuni and 23.5%
for C. coli)14 and Canada (22% for C. jejuni and 12% for
C. coli).15 The prior Australian study reported a much higher
level of ampicillin resistance (50.4–63.6%).5
The major difference between this study and the majority of
similar studies performed in other countries is the absence of
resistance to ciprofloxacin. As fluoroquinolones have not been
registered for use in chickens in Australia, it was not surprising
to find that none of the 125 C. jejuni and 27 C. coli isolates was
resistant to this antibiotic. The prior Australian study reported a
similar absence of ciprofloxacin resistance.5 In contrast, cipro-
floxacin resistance has been reported in the USA (19%)12 and a
range of European nations (14.9% of C. jejuni and 39.6% of C.
coli isolates).11 An absence or near absence of ciprofloxacin
resistance has also been reported from Brazil,16 Canada15 and
Norway.17
In contrast to our findings, other studies have reported that
C. coli isolates show higher levels of resistance than C. jejuni
isolates.11,18 In a Northern Ireland study that found no significant
Table 2. Results of MIC and disc diffusion tests for 125 C. jejuni and 27 C. coli isolates
Antibiotic Species




0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 S I R
Ampicillin jejuni 0 0 4.0 10.4 28.0 35.2 3.2 4.8 11.2 3.2 19.2 82.4 0 17.6
coli 0 0 11.1 7.4 11.1 22.2 40.7 7.4 0 7.4 85.2 0 14.8
Chloramphenicol jejuni 0 0 0 44.0 31.2 23.2 1.6 0 0 98.4 1.6 0
coli 0 0 0 33.3 48.1 18.5 0 0 0 100 0 0
Ciprofloxacin jejuni 72.0 24.8 3.2 0 0 0 0 0 0 100 0 0
coli 66.7 11.1 22.2 0 0 0 0 0 0 100 0 0
Erythromycin jejuni 0 0.8 14.4 50.4 20.0 11.2 3.2 0 0 100 0 0
coli 0 18.5 14.8 22.2 11.1 18.5 3.7 11.1 11.1 88.9 0 11.1
Nalidixic Acid jejuni 0 16.0 55.2 25.6 3.2 0 0 0 0 97.6 0 2.4
coli 0 11.1 55.6 33.3 0 0 0 0 0 100 0 0
Tetracycline jejuni 57.6 16.0 6.4 0.8 0 0 1.6 4.0 4.0 2.4 7.2 19.2 80.0 1.6 18.4
coli 66.7 3.7 14.8 0 0 0 0 0 0 14.8 14.8 85.2 0 14.8
aVertical lines indicate breakpoints for resistance. The white fields denote dilution range tested for each antibiotic. Values above the range denote MIC values
greater than the highest concentration in the range. MICs equal to or lower than the lowest concentration tested are given as the lowest concentration.
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difference between the resistance patterns between C. jejuni and
C. coli, the authors suggested that the uncommon occurrence of
pig husbandry on poultry farms in Northern Ireland might
explain the lower rate of resistance in C. coli isolates.19 It is
notable that none of the broiler farms represented in our study
involved co-location with pig husbandry operations.
Our finding of no multiple resistance (defined as resistance to
four or more different classes of antibiotics) has been also
reported in a number of countries—four European Union
countries,11 Northern Ireland19 and Sweden.13
Our examination of multiple isolates (all genotypically differ-
ent) within four farms demonstrated that isolates within each
farm could be both susceptible and resistant to ampicillin and
tetracycline, a finding that has been reported previously for
ciprofloxacin.20
Overall, we found a good correlation between the disc diffu-
sion methodology of Huysmans and Turnidge9 and the MIC
methodology. For those laboratories that lack the capacity to
undertake MIC-based methodologies, disc diffusion represents,
in our view, an acceptable method for the determination of anti-
microbial resistance patterns in Campylobacter.
Our study has provided solid evidence that the majority of
Queensland poultry isolates of Campylobacter shows little resist-
ance to antibiotics that are either used in the poultry industry or
of public health significance.
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